The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination.
about
ALK Signaling and Target Therapy in Anaplastic Large Cell LymphomaAnaplastic lymphoma kinase: signalling in development and diseaseThe role of the ALK receptor in cancer biologyImmunotherapy meets targeted therapy: will this team end the war against cancer?New molecular insights into peripheral T cell lymphomasA phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcomeING proteins as potential anticancer drug targets.A vaccine targeting angiomotin induces an antibody response which alters tumor vessel permeability and hampers the growth of established tumorsComparative analysis of cancer vaccine settings for the selection of an effective protocol in micePaediatric non-Hodgkin lymphoma - perspectives in translational biologyGingival Anaplastic Large-Cell Lymphoma Mimicking Hyperplastic Benignancy as the First Clinical Manifestation of AIDS: A Case Report and Review of the Literature.Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1).Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK.Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response.Inhibitors of anaplastic lymphoma kinase: a patent review.How to improve the immunogenicity of chemotherapy and radiotherapy.Combining immunotherapy and targeted therapies in cancer treatment.DNA vaccination against oncoantigens: A promise.Novel treatment avenues for peripheral T-cell lymphomas.Preclinical vaccines against mammary carcinoma.Molecular genetics of peripheral T-cell lymphomas.Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease.Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas.Anaplastic lymphoma kinase: Role in cancer and therapy perspective.Maternal Immunization: New Perspectives on Its Application Against Non-Infectious Related Diseases in Newborns.Analysis of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-reactive CD8(+) T cell responses in children with NPM-ALK(+) anaplastic large cell lymphoma.Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors.Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.Genetic alterations in systemic nodal and extranodal non-cutaneous lymphomas derived from mature T cells and natural killer cells.Hematopoietic stem cell transplantation in relapsed ALK+ anaplastic large cell lymphoma in children and adolescents: a study on behalf of the SFCE and SFGM-TC.Pathobiology of anaplastic large cell lymphoma.2011: the immune hallmarks of cancer.Potential therapies for anaplastic lymphoma kinase-driven tumors in children: progress to dateEpitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer.Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung Cancer.Course of anti-ALK antibody titres during chemotherapy in children with anaplastic large cell lymphoma.IRF4 Mediates the Oncogenic Effects of STAT3 in Anaplastic Large Cell Lymphomas.Role and targeting of anaplastic lymphoma kinase in cancer.Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond.Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes.
P2860
Q21129306-4D6AC144-76A3-437B-A791-468CA391CA64Q24312329-A1DC1A17-343C-4985-B19C-D81A4B9DA4BFQ26738384-3C3CC0E9-FBDF-4112-814B-47639904C221Q26769721-1574030E-06ED-4320-BBC4-3E1DBA90AD85Q27026081-15390B5E-77C4-4BED-9513-83455368DC6FQ33556780-0E31F42D-6BC5-49BD-B6B4-BBBF0FCFDACAQ33574029-17CFFB1B-D7F8-4BCC-8584-D90C2C0CFEE1Q35918770-F36BA223-F35E-4F90-AB79-DBDBEDB1BA7FQ36859227-38A82A36-067D-4A13-8A89-8A6E7DE413C8Q36889143-467E549D-4F41-4DC7-9FC2-F60493AB1AD1Q36969196-0233810E-D041-4D46-A9D1-A2DD600A2A1EQ37081609-F03FCE6B-AE12-49F3-826A-38E7BCEA7EEEQ37133621-334D612C-DF57-4F0F-BD04-6C988405018FQ37542092-50BF38D2-555B-45D0-9727-546FF5FE4C5BQ37801664-C14AAD3E-FFAF-4994-8712-C78987D91C86Q37836489-80C81AC4-BB1B-4C17-8EDA-D735FCBE7D26Q37995939-43471A20-E140-4ECE-BAEA-4B96CCC51234Q38022032-C5F09E46-C348-43D4-8D1D-D63430A0FA67Q38045460-E5FD1C6F-4680-46FE-A0CC-7E0515472D14Q38160252-73051C49-350D-4669-B992-DF3E9765D60DQ38183757-DB6C21C5-D540-422A-ACD6-560D98B5F5C3Q38207137-10A86850-A781-49ED-BECF-C044C582A2AAQ38307616-2FE2FF25-01BE-4E1F-A933-FE382D9351B0Q38623421-008C7972-61F9-4394-9966-1FF28A473E70Q38649517-EBD04687-6229-4DE2-8B7B-6EDE373DDB36Q38758254-77D21119-842F-4158-90FA-BF8C4ED9F68CQ38831440-F953EFE7-B74B-4868-9465-63373238BEA6Q38868306-057229F0-2CF5-4CF7-A252-51EE852D5502Q39620024-1AEB81BE-B826-46FF-A55E-249DE3661918Q41141389-0E8A02BE-CBC6-4D98-A49F-BE189DA7BA9FQ41852473-FAC9D0A8-860A-4560-94C5-368108CED83CQ42217850-CC2F4CAB-A735-4373-B914-0EAE069A142CQ42694892-07034DF4-F5EB-4721-8E69-E29F4F409437Q44897019-A67A7B26-B5D9-4ACB-9E44-ADE9E30B053BQ46793262-73A13C77-982C-4961-BE70-8BEA4A3EF0A8Q48150129-F8726256-4AE3-4450-B156-9148702224C6Q49186472-68B638E7-FB5C-48FE-A463-5105193E94DFQ49888052-1C538A57-40DB-4758-A9CA-683C5972F3E1Q52619047-CF1BF720-E54B-48C9-928E-7BD502DC9604Q52679023-6B269110-4152-465A-B56D-812B9C2200E4
P2860
The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination.
@en
The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination.
@nl
type
label
The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination.
@en
The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination.
@nl
prefLabel
The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination.
@en
The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination.
@nl
P2093
P50
P356
P1433
P1476
The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination.
@en
P2093
Chiara Ambrogio
Cinzia Martinengo
Cristina Mastini
Giorgio Inghirami
Guido Forni
Roberto Chiarle
Valentina D'Escamard
P2888
P304
P356
10.1038/NM1769
P407
P577
2008-05-11T00:00:00Z